Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SPGL008 combined with SSGJ-706 with or without chemotherapy in advanced non-small cell lung cancer
CTR20263723Phase 2Active
- Sponsor
- Shenzhen Saibaoer Biopharmaceutical
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SPGL008, SSGJ-706 in non-small cell lung cancer (NSCLC), sponsored by Shenzhen Saibaoer Biopharmaceutical. Started Sep 2026; status: active.
02
Drugs
SPGL008SSGJ-706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263723.